Identification of Potential Therapeutic Targets Inducible Co-Stimulator (ICOS) in Cancer Immunotherapy Using Bioinformatics Analysis
Abstract
Clinical trials testing Inducible Co-Stimulator (ICOS) agonists in cancers are under way. However, Co-expression and Interaction of ICOS at the Gene and Protein Levels, the correlations of ICOS to prognosis and tumor-infiltrating lymphocytes in different cancers remain unclear. ICOS expression was analyzed via the Oncomine database and Tumor Immune Estimation Resource (TIMER) site. Analysis of the expression difference of ICOS shows that the expression of ICOS is significantly increased in BRCA, ESCA, HNSC, KIRC, KIRP, LIHC, STAD and UCEC. We evaluated the influence of ICOS on clinical prognosis using Kaplan-Meier plotter and Gene Expression Profiling Interactive Analysis (GEPIA). This analysis confirmed that low ICOS expression was significantly correlated with poor overall survival (OS) and progression-free survival (PFS) in ovarian cancer. The correlations between ICOS and cancer immune infiltrates were investigated via TIMER. Metascape and Protein-protein interaction (PPI) analysis suggest that ICOS plays an important role in the process of immune activation. ICOS is a potential target for the development of antibody drugs.
References
[2] Li T, Fan J, Wang B, et al. (2017) TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer research 77 (21):e108-e110.
[3] Tang Z, Li C, Kang B, et al. (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic acids research 45 (W1):W98-w102.
[4] Franceschini A, Szklarczyk D, Frankild S, et al. (2013) STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic acids research 41 (Database issue):D808-815.
Copyright (c) 2023 Qingjie Guo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.